CHICAGO (Reuters) - A Zika vaccine Sanofi SA dropped in September under political pressure over pricing produced strong responses in more than 90 percent of those taking part in an early-stage clinical trial, U.S. researchers reported on Monday.
Original Article: Trial results of Zika vaccine Sanofi dropped show promise
NEXT ARTICLE